LBRX vs INVA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LBRX · LB Pharmaceuticals$38.85 ▼ 2.97%
INVA · Innoviva$18.41 ▲ 0.00%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LBRX +140.7%
- INVA -13.5%
Head to head
| Metric | LBRX | INVA |
|---|---|---|
| Price | $38.85 | $18.41 |
| Change today | ▼ 2.97% | ▲ 0.00% |
| Market cap | $1.26B | $1.31B |
| Return, 3 months | -19.4% | -12.5% |
| Return, year to date | +74.5% | -7.9% |
| Return, 1 year | +153.4% | -12.2% |
| P/E (TTM) | 38.3 | 7.8 |
| P/B | 3.0 | 1.2 |
| P/E percentile vs own 5y | 99th | 61st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -1.6% |
| Net profit growth (YoY) | -1,561.0% | -182.2% |
| Gross margin | – | 80.5% |
| Operating margin | – | 38.8% |
| Net margin | – | 44.1% |
| Return on equity | -38.8% | 18.0% |
| Analyst target vs. price | +69.6% | +106.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 44 | 29 |
| 30-day volatility | 63.5% | 34.7% |
| Max drawdown, 1 year | -31.3% | -24.5% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- INVA is the largest of the group by market value.
- LBRX has returned the most over the past year.
- INVA carries the lowest trailing P/E.
- INVA has been the calmest stock over the last 30 days.